Observational, Prospective Clinical Study to Evaluate Biomarkers as Indicators of Acute Bacterial or Viral Infections

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1001 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-09-30

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational prospective study of an in-vitro diagnostic (IVD) assay planned to enroll 632 subjects. The study will be conducted in two stages: Stage A is aimed at identifying individual biomarkers and constructing a multi-parametric diagnostic model, whereas Stage B is aimed at testing the multi-parametric diagnostic model using a fresh cohort of patients.

A collection of clinical, radiological and laboratory data will be gathered in order to establish a final diagnosis. Blood samples will be analyzed and the levels of approximately 700 and 250,000 biomarkers will be determined using immunoassays and molecular measurements respectively.

A final diagnosis will be determined based on a majority decision of a panel of three or more independent physicians. Based on the final diagnosis, the accuracy of individual biomarkers and combined sets of biomarkers for differentiating between distinct groups of patients will be evaluated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A COVID-19 Symptom, Exposure and Immune Response Registry

NCT04348942

COVID-19

COMPLETED

Detection of Bacterial and Viral Pathogens Infection Among Hospitalized Patients Feasibility Study

NCT05399615

Infectious Disease

WITHDRAWN NA

Assessment of the Effectiveness of a Prototype Diagnostic System of Bacterial Respiratory Infections Based on Real-time Sequencing

NCT07303400

Lower Resp Tract Infection

ACTIVE_NOT_RECRUITING

An International Observational Study of Adults With Acute Infection

NCT07069400

Infectious Disease

RECRUITING

Microbial and Cytokine Signatures in Long COVID Patients

NCT07074158

Post-Acute COVID-19 Syndrome

ENROLLING_BY_INVITATION

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

LRTI UTI Gastroenteritis Systemic Infections/Bacteremia/Meningitis Fever Without Source

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

In the Infectious disease group:

* Peak fever \>37.5°C (99.5°F)
* Clinical suspicion of an acute infectious disease
* Symptoms duration ≤ 12 days

In the Non-infectious disease control group:

\- A non-infectious disease or healthy individuals

Exclusion Criteria

Patients who will meet one or more of the following criteria will be excluded from the study:

* Evidence of another episode of acute infectious disease in the last two weeks
* Diagnosed congenital immune deficiency (CID)
* Current treatment with immunosuppressive therapy such as: Active chemotherapy,Post-transplant drugs,High dose steroids (\>1 mg/kg/day prednisone or equivalent).
* Active radiotherapy
* Immune-modulating/suppressive drugs including monoclonal antibodies, intravenous immunoglobulin (IVIG), cyclosporine, and anti-TNF agents
* Current treatment with immune stimulants such as: Interleukin (IL)-2, Granulocyte-Monocytes/Granulocyte colony-stimulating factor (GM/G-CSF),Interferon.
* An active hematological malignancy
* A diagnosis of myelodysplastic syndrome or myeloproliferative disease
* A proven or suspected human immunodeficiency virus (HIV)-1, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection

Minimum Eligible Age

1 Month

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes